Cellectar Biosciences, Inc. (CLRB)
2.38
-0.03
(-1.24%)
USD |
NASDAQ |
Sep 09, 13:39
Cellectar Biosciences Shareholders Equity (Quarterly) : 29.87M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 29.87M |
| March 31, 2026 | 4.717M |
| December 31, 2025 | 9.919M |
| September 30, 2025 | 9.379M |
| June 30, 2025 | 7.467M |
| March 31, 2025 | 9.635M |
| December 31, 2024 | 15.68M |
| September 30, 2024 | 16.55M |
| June 30, 2024 | 13.76M |
| March 31, 2024 | 13.88M |
| December 31, 2023 | -13.78M |
| September 30, 2023 | 4.567M |
| June 30, 2023 | -0.467M |
| March 31, 2023 | 7.334M |
| December 31, 2022 | 9.535M |
| September 30, 2022 | 12.75M |
| June 30, 2022 | 20.19M |
| March 31, 2022 | 27.21M |
| December 31, 2021 | 33.05M |
| September 30, 2021 | 38.59M |
| June 30, 2021 | 43.98M |
| March 31, 2021 | 49.78M |
| December 31, 2020 | 54.79M |
| September 30, 2020 | 16.22M |
| June 30, 2020 | 19.99M |
| Date | Value |
|---|---|
| March 31, 2020 | 5.246M |
| December 31, 2019 | 9.059M |
| September 30, 2019 | 12.23M |
| June 30, 2019 | 15.99M |
| March 31, 2019 | 9.847M |
| December 31, 2018 | 13.26M |
| September 30, 2018 | 16.88M |
| June 30, 2018 | 4.707M |
| March 31, 2018 | 7.452M |
| December 31, 2017 | 10.75M |
| September 30, 2017 | 7.593M |
| June 30, 2017 | 10.86M |
| March 31, 2017 | 13.75M |
| December 31, 2016 | 13.54M |
| September 30, 2016 | 7.717M |
| June 30, 2016 | 9.829M |
| March 31, 2016 | 2.577M |
| December 31, 2015 | 1.650M |
| September 30, 2015 | 0.6802M |
| June 30, 2015 | 2.373M |
| March 31, 2015 | 4.588M |
| December 31, 2014 | 10.75M |
| September 30, 2014 | 9.877M |
| June 30, 2014 | -2.541M |
| March 31, 2014 | -0.7273M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 1.307B |
| Alnylam Pharmaceuticals, Inc. | 1.354B |
| Anika Therapeutics, Inc. | 137.28M |
| Savara, Inc. | 143.66M |
| Vericel Corp. | 370.04M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 36.64M |
| Total Liabilities (Quarterly) | 6.767M |
| Debt to Equity Ratio | 0.0513 |
| Current Ratio | 6.659 |
| Net Debt Paydown Yield | -0.92% |